AMG 337

Catalog No.S8167

For research use only.

AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the Met (c-Met) receptor with an IC50 of 1 nM.

AMG 337 Chemical Structure

CAS No. 1173699-31-4

Selleck's AMG 337 has been cited by 2 Publications

Purity & Quality Control

Choose Selective c-Met Inhibitors

Other c-Met Products

Biological Activity

Description AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the Met (c-Met) receptor with an IC50 of 1 nM.
MET receptor [1]
(Cell-free assay)
MET(H1094R) [1]
(Cell-free assay)
MET(M1250T) [1]
(Cell-free assay)
MET(V1092I) [1]
(Cell-free assay)
1 nM 1 nM 4.7 nM 21.5 nM
In vitro

AMG 337 potently inhibits the enzymatic activity of WT MET and a subset of MET mutants found in papillary renal cell carcinoma. The inability of AMG 337 to inhibit the Y1230 and D1228 mutants is likely the result of a disruption of the inactive confirmation of the activation loop in the MET kinase domain. AMG 337 also inhibits cell based HGF-induced MET phosphorylation in PC3 cells with IC50 of 5nM. AMG 337 inhibits proliferation in MET-dependent cancer cell lines. AMG 337 inhibits signaling through the PI3K and MAPK pathways in MET-amplified gastric cancer cell lines resulting in profound effects on cell proliferation and survival[1].

In vivo AMG 337 exhibits impressive potency with >90% inhibition of Gab-1 phosphorylation at a dose of 0.75 mg/kg (32 nmol/L free-drug concentration). AMG 337 is well tolerated at continuously administered doses that corresponded with complete MET inhibition for 24 hours, suggesting that AMG 337 has the preclinical attributes required to test the role of MET in human cancer[1].

Protocol (from reference)

Cell Research:


  • Cell lines: Human cancer cell lines
  • Concentrations: serial dilution(a top concentration of 3 mmol/L.)
  • Incubation Time: 72 h
  • Method:

    To evaluate the effect of AMG 337 on viability, cells are seeded in 96-well plates at an optimal density to ensure proliferation throughout the duration of the experiments. Cells are treated for 72 hours with a 10-point, 3-fold, serial dilution of AMG 337 using a top concentration of 3 mmol/L. Viability is measured with the CellTiter-Glo Luminescent Cell Viability Assay.

Animal Research:


  • Animal Models: Female CD1 nu/nu or athymic nude mice(Tumor xenograft models)
  • Dosages: 0.1, 0.5, 0.75, 1, 2, or 3 mg/kg
  • Administration: by oral gavage

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 463.46


CAS No. 1173699-31-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02096666 Completed Drug: AMG 337 Stomach Neoplasms Amgen April 15 2014 Phase 1|Phase 2
NCT02016534 Terminated Drug: AMG 337 Stomach Neoplasms Amgen February 2014 Phase 2
NCT01253707 Completed Drug: AMG 337 Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors Amgen December 2010 Phase 1

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy AMG 337 | AMG 337 supplier | purchase AMG 337 | AMG 337 cost | AMG 337 manufacturer | order AMG 337 | AMG 337 distributor